Patents by Inventor Emma Watson

Emma Watson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMPROVED THROMBIN INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC CONDITIONS
    Publication number: 20230416341
    Abstract: The invention relates to the treatment of thromboembolic conditions, to fibrin clot formation and related thrombin activity, and to preparation of compounds, in particular, peptides and polypeptides for inhibiting, or for modifying the cleavage of fibrinogen by thrombin.
    Type: Application
    Filed: June 19, 2020
    Publication date: December 28, 2023
    Applicants: THE UNIVERSITY OF SYDNEY, THE HEART RESEARCH INSTITUTE LTD
    Inventors: Richard J PAYNE, Emma WATSON, Shaun Phillip JACKSON
  • Use of therapeutic agents
    Patent number: 11066671
    Abstract: The specification relates to the use of Mcl-1 inhibitors to promote apoptosis in vascular endothelial cells undergoing neovascularisation in disease states.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: July 20, 2021
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Leigh Coultas, Grant Dewson, Emma Watson
  • Poly(diol fumarates) and poly(diol fumarate-co-succinates)
    Patent number: 10835614
    Abstract: The disclosure relates to a class of diol-based, unsaturated aliphatic polyesters that biodegrade into monomers capable of mitigating infection. These poly(diol fumarates) (PDFs) and poly(diol fumarate-co-succinates) (PDFSs), can be crosslinked to form networks of scaffolds with antimicrobial degradation products. Both the diol carbon length and the degree of available double bonds are tunable, resulting in a highly controllable class of antimicrobial polymers useful for cell scaffolds and drug delivery systems and devices.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: November 17, 2020
    Assignees: William Marsh Rice University, Board of Regents, The University of Texas System
    Inventors: Alexander Mitchell Tatara, Emma Watson, Antonios G. Mikos, Dimitrios P. Kontoyiannis
  • USE OF THERAPEUTIC AGENTS
    Publication number: 20200157539
    Abstract: The specification relates to the use of Mcl-1 inhibitors to promote apoptosis in vascular endothelial cells undergoing neovascularisation in disease states
    Type: Application
    Filed: November 12, 2019
    Publication date: May 21, 2020
    Inventors: Leigh COULTAS, Grant DEWSON, Emma WATSON
  • POLY(DIOL FUMARATES) AND POLY(DIOL FUMARATE-CO-SUCCINATES)
    Publication number: 20190091343
    Abstract: The disclosure relates to a class of diol-based, unsaturated aliphatic polyesters that biodegrade into monomers capable of mitigating infection. These poly(diol fumarates) (PDFs) and poly(diol fumarate-co-succinates) (PDFSs), can be crosslinked to form networks of scaffolds with antimicrobial degradation products. Both the diol carbon length and the degree of available double bonds are tunable, resulting in a highly controllable class of antimicrobial polymers useful for cell scaffolds and drug delivery systems and devices.
    Type: Application
    Filed: September 28, 2018
    Publication date: March 28, 2019
    Inventors: Alexander Mitchell Tatara, Emma Watson, Antonios G. Mikos, Dimitrios P. Kontoyiannis
  • USE OF THERAPEUTIC AGENTS
    Publication number: 20180291373
    Abstract: The specification relates to the use of Mcl-1 inhibitors to promote apoptosis in vascular endothelial cells undergoing neovascularisation in disease states.
    Type: Application
    Filed: October 26, 2015
    Publication date: October 11, 2018
    Inventors: Leigh COULTAS, Grant DEWSON, Emma WATSON
  • URICASE COMPOSITIONS AND METHODS OF USE
    Publication number: 20110171268
    Abstract: Compositions containing uricase are disclosed. Methods of treating a disorder associated with elevated uric acid concentrations using uricase are also described. Compositions containing uricase and catalase are also disclosed. Methods of treating a disorder associated with elevated uric acid concentrations using uricase and catalase are also described.
    Type: Application
    Filed: March 24, 2009
    Publication date: July 14, 2011
    Applicant: Althea Technologies, Inc.
    Inventors: Bhami Shenoy, Danica Grujic, Reena Patel, Vinney George, Margaret Mcgrath, Nazer Khalaf, Emma Watson